Production (Stage)
Context Therapeutics Inc.
CNTX
$0.6186
-$0.0108-1.72%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.67% | 9.85% | 10.67% | -6.96% | -13.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.61% | -37.83% | 202.59% | -41.64% | -42.65% |
| Operating Income | -44.61% | 37.83% | -202.59% | 41.64% | 42.65% |
| Income Before Tax | -24.80% | 50.62% | -197.20% | 55.01% | 41.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.80% | 50.62% | -197.20% | 55.01% | 41.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.80% | 50.62% | -197.20% | 55.01% | 41.86% |
| EBIT | -44.61% | 37.83% | -202.59% | 41.64% | 42.65% |
| EBITDA | -44.60% | 37.85% | -202.69% | 41.65% | 42.66% |
| EPS Basic | 79.06% | 90.38% | 41.04% | 86.94% | 41.86% |
| Normalized Basic EPS | 79.04% | 90.38% | 41.04% | 86.95% | 41.84% |
| EPS Diluted | 79.06% | 80.33% | 41.04% | 86.94% | 41.86% |
| Normalized Diluted EPS | 79.04% | 90.38% | 41.04% | 86.95% | 41.84% |
| Average Basic Shares Outstanding | 496.18% | 413.15% | 404.07% | 244.22% | 0.00% |
| Average Diluted Shares Outstanding | 496.18% | 413.15% | 404.07% | 244.22% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |